Investing

11 Analyst Stocks Under $10 With Massive Upside Targets

Gaiam Inc. (NASDAQ: GAIA) showed that revenues rose 13% to its top 25 customers, but the West Coast port shutdown and stocking level issues at the largest customer hurt earnings to where it lost $3.9 million in the quarter. Roth Capital came out and started the yoga-themed player with a Buy rating and $8.00 price target ahead of the report. This was against a $6.47 close, but shares rose late in the week to end up at $6.94 on Friday’s close. Gaiam has a consensus price target north of $9.00.

Nokia Corp. (NYSE: NOK) had a solid week on news that Uber may spend $3 billion to buy its HERE mapping technology, if it beats out other carmakers interested. Nokia shares closed out the week at $6.93, versus a low of just under $6.40 this week. UBS stepped up to the plate here and raised Nokia to Buy from Neutral. Alcatel-Lucent’s better than expected earnings and multiple analyst upgrades also helped out Nokia shares last week.

Quantum Corp. (NYSE: QTM) provides scalable data storage and data protection solutions for enterprises and small businesses, putting it in a hot niche of late. The firm Northland Securities raised its rating last week to Outperform from Market Perform, but what stood out was a doubling of the price target to $3.00 in the call. This was against a prior $2.03 closing price, and Quantum closed at $2.06 on Friday, leaving almost 50% upside if the firm is right. Only three analysts cover this stock, and the other two price targets are listed as $2.50 and $3.50. Quantum has a 52-week range of $1.02 to $2.22 and a market cap of $528 million.

ALSO READ: Banks and States With the Most Branch Closings: The Rise of Mobile Banking

Scorpio Bulkers Inc. (NYSE: SALT) lives and dies by transporting and shipping dry bulk commodities like grain, fertilizer, coal and ore. Trading at $2.65, it has a 52-week range of $1.30 to $9.46, which should offer a clue on how volatile it is. This week we saw that UBS raised its rating to Buy from Neutral, and the firm gave a price target of $3.50. This was versus a $2.50 closing price then, and shares closed at $2.65 on Friday. If UBS turns out to be right, this implies more than 30% upside. If UBS seems too aggressive, consider that Scorpio Bulkers has a consensus price target closer to $4.00.

Standard Pacific Corp. (NYSE: SPF) may be down over the past month, but after earnings this homebuilder was raised to Buy from Hold at Evercore ISI. The firm also gave a $10.00 price target in the call. Standard Pacific had closed at $8.20 ahead of the call, and shares went out at $8.29 on Friday. Despite a low stock price, Standard Pacific has almost a $2.3 billion market cap. It also has a 52-week range of $6.52 to $9.19 and a consensus price target of $9.25. Investors also should know that $10.00 is the highest price target.

Boulder Brands Inc. (NASDAQ: BDBD) met earnings expectations this week and serious interest, and controversy, remains with this gluten-free food maker. Janney Capital Markets reiterated its Buy rating and $11 price target after earnings. While the call came at a prior close of $9.99, Boulder Brands shares closed down at $9.51. Also, this $11 target is under the $11.95 consensus price target and is against a 52-week range of $7.77 to $15.47. Canaccord Genuity maintained its Hold rating, but that firm has a $12 price target. Janney’s note on Boulder Brands said:

Consumption increased 18% in the Natural segment. This was strong performance, driven by strength in Udi’s and EVOL, partially offset by difficult comps and lower consumption trends in Glutino. Gluten-free consumption in the combined Udi’s and Glutino brands increased 11.9%; sales increased 3% as shipments trailed retail takeway volumes. … We maintain our Buy rating on the stock with fair value price of $11.00 per share. The stock is cheap on an EV/Sales ratio valuation, and comps should improve throughout 2015.

Canaccord Genuity’s note on Boulder Brands said:

We continue to view the Udi’s, EVOL & Earth Balance brands as growth engines whose collection value likely supports the majority of the valuation on a sum-of-the-parts analysis. However, gluten-free category is more modest as the category matures, limiting the ability to offset double-digit declines at Smart Balance. We maintain our HOLD rating, but our confidence is boosted after an in-line first quarter performance.

ALSO READ: Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.